A Novel, Effective, and Efficient Strategy for Treating Sickle Cell Vaso-occlusive Events in the Infusion Center Setting

Coagulation factors are proteins in our blood, and they help form blood clots to stop bleeding when is needed.

There are several types of coagulation factors that are all important for making blood clots as a physiological response to a stimulus. In case of sickle cell anaemia, it is known that in the pathogenesis of vaso-occlusive events a key factor is hypercoagulability state. Hypercoagulable state is a condition in which you are more likely to develop blood clots in the absence of bleeding.

In this context, coagulation factor XII (FXII) it has been postulated that could be a key role molecule in the pathogenesis of vaso-occlusive crises. In animal models, the inhibition of this coagulation factor reduced vaso-occlusive events, inflammation and thrombosis.

Coagulation factor XII (FXII) is a promising therapeutic target for further research in a way to reduce thrombotic complications and crises in patients with sickle cell anaemia.